奈达铂联合替加氟治疗晚期头颈部癌的临床研究

Clinical Observation of Nedaplatin Combined with Tegafur to Treat Advanced Head and Neck Cancer

目的:观察奈达铂(NDP)联合替加氟(FT-207)治疗晚期头颈部癌的疗效及毒副反应。方法:对44例晚期头颈部癌患者给予NDP 80mg//m^2～100mg/m^2静脉滴注2小时以上,第1天,FT-207 600mg/m^2,第1天～5天,静脉滴注8小时,每21天为一周期,至少应用2周期。结果:44例患者中可评价疗效42例,初治19例,CR 2例,PR 9例,有效率57.9%(11/19);复治23例,CR 1例,PR 8例,有效率39.1%(9/23);近期客观有效率47.6%(20/42),中位进展时间(TTP)5.1个月,中位生存时间(MST)10.5个月,主要毒副反应为骨髓抑制,恶心,呕吐,但患者均能耐受。42例可评价毒副反应的患者中,有3例(7.1%)出现Ⅲ度中性粒细胞降低,5例(11.9%)出现Ⅲ度～Ⅳ度血小板降低。结论:NDP联合FT-207化疗对晚期头颈部癌疗效较好,毒副反应较轻,可作为晚期头颈部癌的主要化疗方案。

Objective： To observe the clinical efficacy and toxicity of nedaplatin combined with tegafur to treat patients with advanced head and neck cancer. Methods ： 44 patients with advanced head and neck cancer were included in the study. The patients were given NDP at a dose of 80mg/m2 - 100mg/m2 intravenously at least 2 hours on dI and FT-207 at a dose of 600mg/m2 for 8 hours on d1 -d5 ,every 21 days as a cycle. Each patients was treated at least two cycles. Results： Among the 44 patients, 42 patients were evaluable for efficacy and toxicity. In 19 patients with no prior history of chemotherapy,2 achieved CR and 9 PR, the response rate was 57.9% . There were 23 patients who had ever received postoperative adjuvant chemotherapy, 1 obtained CR and 8 PR , the response rate was 39.1%. The overall response rate was 47.6%. The median response duration was 5.1 months and the median survival time was 10.5 months. The main toxicity was myelosuppression, nausea and vomiting, but were mild and well tolerated. Grade 3 to 4 neutropeuia was only observed in three patients （ 7.1% ） and thrombocytopenia was five （ 11.9% ）. Conclusion： NDP combined with FT- 207 is effective and tolerable in the treatment of advanced head and neck cancer .